Shenzhen Kangtai Biological Products (300601.SZ): The application for clinical trials of bivalent inactivated enterovirus vaccine (Vero cells) has been accepted.

Shenzhen Kangtai Biological Products (300601.SZ) announced that its wholly-owned subsidiary, Beijing Minhai Biotechnology Co., Ltd. (referred to as "Minhai Biotechnology"), recently received a notice of acceptance issued by the National Medical Products Administration, approving the clinical trial application for the development of a bivalent inactivated vaccine against enterovirus (Vero cells) and a quadrivalent inactivated vaccine against enterovirus (Vero cells) by Minhai Biotechnology. After careful consideration by the company and its wholly-owned subsidiary Minhai Biotechnology, it has been decided to terminate the clinical trial of the recombinant enterovirus type 71 vaccine (Hansen yeast) in order to rationalize the allocation of the company's research and development resources and focus on key research and development projects.